Dataset opportunity
Robsurgical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Robsurgical, usable for Diagnostic AI and Computer Vision.
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market = $1.70 Billion in 2024, CAGR 25.8% (source: Global Market Direct)
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-22
Time runs out for Vicarious Surgical
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Robsurgical holds a proprietary Medical Imaging Dataset for surgical applications, which integrates a rich image_collection with contextual iot_data from surgical devices and associated `medical_records`. This multi-modal combination provides a comprehensive foundation for developing and validating high-precision Diagnostic AI models, offering deep clinical insights that are crucial for advanced automated diagnostics.
The global AI in medical imaging market is a rapidly expanding sector, valued at $1.70 billion in 2024 and projected to grow at a 25.8% CAGR. [3] Despite access complexities due to the dataset's pre-commercial status (CE Mark pending) and the need for strict adherence to GDPR and advanced anonymization protocols, its clinical depth and rarity represent a significant competitive advantage for AI developers aiming to capture value in this high-growth market. [3] ⚠ Diligence (valuable data, access to negotiate): Pre-commercial status (CE Mark pending) limits current commercial data flow; Medical data subject to strict healthcare regulations and GDPR; Surgical videos require advanced anonymization · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Robsurgical holds a proprietary dataset of medical images from a clinical trial of its Bitrack surgical robot. This unique data, specifically from urology procedures like nephrectomies, is a critical asset for medical AI firms developing next-generation diagnostic AI and surgical analytics tools. In a market projected to reach $1.70 billion in 2024 and growing at over 25% annually, such rare, procedure-specific visual data offers a significant competitive advantage.
See dimension details ↓- Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by the AI in medical imaging market's rapid expansion at a 25.8% CAGR, which creates a strong need for unique, high-quality clinical data to train next-generation diagnostic tools. [3]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - ICP Audit100
✓ good target — This is an ideal target: a MedTech SME whose core business is selling a surgical robot, which generates vast amounts of valuable, dormant operational and imaging data as a by-product. Issues: The company's website mentions a focus on digitization, including 'Artificial Intelligence, Big Data, medical imaging, vision systems and virtual reality' [15].
- Deep Qualification80
⚠ needs review — Rob Surgical is a pre-commercial medical device manufacturer, not a data seller. It develops the Bitrack surgical robot, and the associated imaging and operational data generated during trials is a dormant byproduct. The recent CE mark approval is a major trigger for commercialization, but data access remains highly restricted by GDPR and medical regulations, with ownership unclear from public sources. [business model = tooling_vendor]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This evidence points to time-series operational data from the surgical robot, which is valuable for training AI to analyze and improve robotic surgical efficiency.
Image collection
This confirms the existence of proprietary images from a clinical trial involving nephrectomies, a core asset for any company building surgical diagnostic AI.
Medical records / imaging
This evidence links the dataset to the high-value specialty of urology, providing the specific procedural context required to train and validate specialized surgical AI models.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Robsurgical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.70 Billion in 2024, CAGR 25.8% (source: Global Market Direct). Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Quantumsurgical — Medical Imaging Dataset Opportunity
View opportunity →healthcareCardiofocus — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareDistalmotion — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- 5 Mistakes That Drive Buyers Away3 min read
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read